Patent Assignment
Reel/Frame 042418/0774
Security Interest
Recorded: 2017-05-08
Pages: 158
Assignor
PTC THERAPEUTICS, INC.
Executed: 2017-05-05
Assignee
MIDCAP FINANCIAL TRUST, AS AGENT
7255 WOODMONT AVENUE, SUITE 200, C/O MIDCAP FINANCIAL SERVICES, LLC, AS SERVICER, BETHESDA, MARYLAND, 20814
Covered Properties
(135)
Novel Cystic Fibrosis Treatment
Patent:
5,840,702 →
Application:
08/620,866 →
Detection Method for Monitoring Beta Tubulin Isotype Specific Modification
Patent:
6,306,615 →
Application:
09/377,554 →
Methods of Assaying for Compounds That Inhibit Premature Translation Termination and Nonsense-Mediated Rna Decay
Patent:
6,458,538 →
Application:
09/461,508 →
Aminoglycoside Treatment for Lysosomal Storage Diseases
Methods of Assaying for Compounds That Inhibit Premature Translation Termination and Nonsense-Mediated Rna Decay
Methods for Identifying Small Molecules That Modulate Premature Translation Termination and Nonsense Mrna Decay
Methods for Identifying Small Molecules That Modulate Premature Translation Termination and Nonsense Mediated Mrna Decay
Methods and Systems for the Identification of Rna Regulatory Sequences and Compounds that Modulate their Function
Application:
10/542,255 →
Publication:
US 2008/0227085
Methods for identifying compounds that modulate untranslated region-dependent gene expression and methods of using same
Methods of Identifying Compounds That Target Trna Splicing Endonuclease and Uses of Said Compounds as Anti-Fungal Agents
Bowman-Birk Inhibitor Compositions for Treatment of Muscular Atrophy and Degenerative Muscle Disease
Tetra-Cyclic Carboline Derivatives Useful in the Inhibition of Angiogenesis
Nucleoside Compounds and Their Use for Treating Cancer and Diseases Associated with Somatic Mutations
1,2,4-Oxadiazole Benzoic Acid Compounds and Their Use for Nonsense Suppression and the Treatment of Disease
Methods and agents for screening for compounds capable of modulating VEGF expression
Methods and agents for screening for compounds capable of modulating gene expression
1,2,4-Oxadiazole Benzoic Acid Compounds and Their Use for Nonsense Suppression and the Treatment of Disease
Ureido Substituted Benzoic Acid Compounds and Their Use for Nonsense Suppression and the Treatment of Disease
Acetylamino Benzoic Acid Compounds and Their Use for Nonsense Suppression and the Treatment of Disease
Use of Nucleoside Compounds for Nonsense Suppression and the Treatment of Genetic Diseases
Carboline Derivatives Useful in the Inhibition of Angiogenesis
Carboline Derivatives Useful in the Treatment of Cancer
Methods for Treating Hepatitis C
Methods for Treating Hepatitis C
Benzoic Acid or Benzoate Substituted 1,2,4-Oxadiazole Compounds and Their Use for the Treatment of Disease
Methods for Treating Hepatitis C
3-[5-(2-Fluoro-Phenyl)-[1,2,4]Oxadiazol-3-Yl]-Benzoic Acid, Compositions, and Methods for the Use Thereof
Substituted 1,2,4-Oxadiazoles, Compositions and Methods of Use
Compounds for Nonsense Suppression, Use of These Compounds for the Manufacture of a Medicament for Treating Somatic Mutation-Related Diseases
Application:
11/577,176 →
Publication:
US 2008/0269191
Pyrazole or Triazole Compounds and Their Use for the Manufacture of a Medicament for Treating Somatic Mutation-Related Diseases
Compounds for Nonsense Suppression, and Methods for Their Use
1,3,4-Oxadiazole Benzoic Acid Compounds and Their Use for Nonsense Suppression and the Treatment of Disease
Compounds for Nonsense Suppression, and Methods for Their Use
Methods for Treating Hepatitis C
Methods for Treating Hepatitis C
Tetrahydrocarbazoles as Active Agents for Inhibiting Vegf Production by Translational Control
Substituted Phenols as Active Agents Inhibiting Vegf Production
1,2,4-Oxadiazole Benzoic Acid Compositions and Their Use in Bioassays
Administration of Carboline Derivatives Useful in the Treatment of Cancer and Other Diseases
Inhibition of Vegf Translation
Use of Acetylamino Benzoic Acid Compounds for Nonsense Suppression and the Treatment of Disease
Cell Based Methods And Systems For The Identification Of Rna Regulatory Sequences And Compounds That Modulate Their Functions
Processes for the Preparation of 1,2,4-Oxadiazole Benzoic Acids
Hydroxylated 1,2,4-Oxadiazole Benzoic Acid Compounds and Composistions Thereof
Crystalline Forms of 3-[5-(2-Fluorophenyl)-[1,2,4]Oxadiazol-3-Yl]-Benzoic Acid
Methods for Dosing an Orally Active 1,2,4-Oxadiazole
Methods for dosing an orally active 1,2,4-oxadiazole
Ureido Substituted Benzoic Acid Compounds and Their Use for Nonsense Suppression and the Treatment of Disease
Methods of Screening for Compounds for Treating Muscular Dystrophy Using Utrn Mrna Translation Regulation
Patent:
8,283,115 →
Application:
12/143,705 →
Methods of Screening for Compounds for Treating Spinal Muscular Atrophy Using Smn Mrna Translation Regulation
Patent:
8,283,116 →
Application:
12/144,577 →
Methods for the Production of Functional Protein from Dna Having a Nonsense Mutation and the Treatment of Disorders Associcated Therewith
Rna Processing Protein Complexes and Uses Thereof
Carboline Derivatives Useful in the Inhibition of Angiogenesis
Processes for the Preparation of 1,2,4-Oxadiazole Benzoic Acids
Methods for the Synthesis of 1,2,4-Oxadiazole Benzoic Acid Compounds
1,2,4-Oxadiazole Benzoic Acid Compositions and Their Use in Bioassays
Carboline Derivatives Useful in the Inhibition of Angiogenesis
Pharmaceutical Compositions of 1,2,4-Oxadiazole Benzoic Acid and Their Use for the Treatment of Disease
Methods of Identifying Compounds That Target Trna Splicing Endonuclease and Uses of Said Compounds as Anti-Proliferative Agents
Methods for Treating Hepatitis C
Crystalline Forms of 3-[5-(2-Fluorophenyl)-[1,2,4]Oxadiazol-3-Yl]-Benzoic Acid
Ureido Substituted Benzoic Acid Compounds and Their Use for Nonsense Suppression and the Treatment of Disease
Methods for Treating Spinal Muscular Atrophy
Methods for Screening for Compounds for Treating Cancer
Compounds for Nonsense Suppression and Methods for Their Use
Screening assays for compounds that modulate programmed ribosomal frameshifting
Methods for Treating Spinal Muscular Atrophy
Use of Bbi/Bbic for Treatment of Muscular Atrophy and Degenerative Muscle Disease
1,2,4-Oxadiazole Benzoic Acid Compositions
Compounds and Methods for Antiviral Treatment
HCV Inhibitor and Therapeutic Agent Combinations
Hcv Inhibitor and Therapeutic Agent Combinations
Combinations of a Hcv Inhibitor Such as Bicyclic Pyrrole Derivatives and a Therapeutic Agent
Methods for Treating Prostate Conditions
Methods for Treating Kaposi Sarcoma
Methods for Treating Brain Tumors
Application:
13/321,252 →
Publication:
US 2012/0157402
Processes for the Preparation of Substituted Tetrahydro Beta-Carbolines
Application:
13/321,262 →
Publication:
US 2012/0136154
Hydroxylated 1,2,4-Oxadiazole Benzoic Acid Compounds, Compositions Thereof and Their Use in Bioassays
1,2,4-Oxadiazole Benzoic Acid Compositions and Their Use in Bioassays
1,2,4-Oxadiazole Benzoic Acids
SURVIVAL MOTOR NEURON GENE (SMN2) mRNA CONSTRUCTS FOR POST- TRANSCRIPTION REGULATION
Patent:
9,394,539 →
Application:
13/646,924 →
METHODS OF SCREENING FOR COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY USING mIGF1 mRNA TRANSLATION REGULATION
Patent:
8,741,572 →
Application:
13/646,943 →
Methods for Treating Viral Conditions
Application:
13/699,849 →
Publication:
US 2013/0171103
Crystalline Forms of 3-[5-(2-Fluorophenyl)-[1,2,4]Oxadiazol-3-Yl]-Benzoic Acid
Methods For Identifying Compounds That Modulate Untranslated Region-Dependent Gene Expression And Methods Of Using Same
Methods for Using 1,2,4-Oxadiazole Benzoic Acid Compounds
Compositions for an Orally Active 1,2,4-Oxadiazole for the Treatment of Disease
Antibacterial Compounds and Methods for Use
Antibacterial Compounds and Methods for Use
Antibacterial Compounds and Methods for Use
Application:
14/241,649 →
Publication:
US 2015/0038438
METHODS OF SCREENING FOR COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY USING HUMAN ALPHA7 INTEGRIN mRNA TRANSLATION REGULATION
Patent:
9,376,725 →
Application:
14/260,873 →
Crystalline Forms of 3-[5-(2-Fluorophenyl)-[1,2,4]Oxadiazol-3-Yl]-Benzoic Acid
Compounds for Nonsense Suppression, and Methods for Their Use
Methods for Using 1,2,4-Oxadiazole Benzoic Acid Compounds
Compounds for Treating Spinal Muscular Atrophy
Compounds for Treating Spinal Muscular Atrophy
Compounds for Treating Spinal Muscular Atrophy
Substituted Reverse Pyrimidine Bmi-1 Inhibitors
Methods for Treating Viral Infections
Application:
14/569,212 →
Tetrahydrocarbazoles as Active Agents for Inhibiting Vegf Production by Translational Control
Compositions of 1,2,4-Oxadiazole Benzoic Acid Compounds and Methods for Their Use
Methods for Treating Viral Infections
Application:
14/709,951 →
Publication:
US 2015/0344877
Methods And Agents For Screening For Compounds Capable Of Modulating Gene Expression
Pyrazole or Triazole Compounds and Their Use for the Manufacture of a Medicament for Treating Somatic Mutation-Related Diseases
Application:
14/733,615 →
Publication:
US 2015/0274674
Substituted Pyrimidine Bmi-1 Inhibitors
Compositions of 1,2,4-Oxadiazole Benzoic Acid Compounds and Methods for Their Use
Methods for Dosing an Orally Active 1,2,4-Oxadiazole for Nonsense Mutation Suppression Therapy
Substituted Triazine Bmi-1 Inhibitors
Methods for the Production of Functional Protein from Dna Having a Nonsense Mutation and the Treatment of Disorders Associated Therewith
Application:
15/044,225 →
Publication:
US 2016/0199357
Crystalline Forms of 3-[5-(2-Fluorophenyl)-[1,2,4]Oxadiazol-3-Yl]-Benzoic Acid for the Treatment of Disease
Methods for Modulating the Amount of Rna Transcripts
Pharmaceutical Compositions and Salts of a 1,2,4-Oxadiazole Benzoic Acid
Compounds for Nonsense Suppression, and Methods for Their Use
Application:
15/130,318 →
Publication:
US 2016/0229818
Compounds for Treating Spinal Muscular Atrophy
Compositions for an Orally Active 1,2,4-Oxadiazole for the Treatment of Disease
Methods of Treatment Using a 1,2,4-Oxadiazole Benzoic Acid
Application:
15/316,415 →
Publication:
US 2017/0196842
Methods for Dosing an Orally Active 1,2,4-Oxadiazole for Nonsense Mutation Suppression Therapy
Compounds for Nonsense Suppression, and Methods for Their Use
Application:
15/475,240 →
Publication:
US 2017/0204073
Pharmaceutical Compositions and Salts of a 1,2,4-Oxadiazole Benzoic Acid
Application:
62/009,111 →
Substituted Polycyclic Antibacterial Compounds
Application:
62/038,123 →
Bicyclic and Tricyclic Substituted 2-Pyridinone Antibacterial Compounds
Application:
62/048,038 →
Monocyclic Substituted 2-Pyridinone Antibacterial Compounds
Application:
62/048,085 →
Polycyclic 2-Pyridinone Antibacterial Compounds
Application:
62/048,151 →
Bicyclic and Tricyclic Substituted 2-Pyridinone Antibacterial Compounds
Application:
62/048,166 →
Fused Polycyclic 2-Pyridinone Antibacterial Compounds
Application:
62/098,876 →
Compounds for Improving mRNA Splicing
Application:
62/104,547 →
Methods for Modulating Rna Splicing
Application:
62/168,726 →
Use of an Aminoglycoside for Nonsense Mutation Suppression and the Treatment of Disease
Application:
62/171,838 →
Compounds for Improving mRNA Splicing
Application:
62/180,380 →
Methods for Treating Epilepsy
Application:
62/248,891 →
Hydrogen Isotope-Enriched Analogues of 1,2,4-Oxadiazole Benzoic Acid Compounds, Compositions and Uses Thereof
Application:
62/255,751 →
Methods for Treating Huntington's Disease
Application:
62/265,652 →
Methods of Administering Deflazacort Therapy
Application:
62/342,628 →
Methods of Administering Deflazacort Therapy
Application:
62/408,482 →
Methods for Modulating RNA Splicing
Application:
62/426,619 →
Related Assignments
(9)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest
Oct 25, 2007
From: MOON, YOUNG-CHOON; CAO, LIANGXIAN; TAMILARASU, NADARAJAN; QI, HONGYAN
To: PTC THERAPEUTICS, INC.
Reel/Frame 020016/0155 →
Confirmatory License
May 8, 2008
From: THE UNIVERSITY OF ALABAMA AT BIRMINGHAM
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 020919/0144 →
Executive Order 9424, Confirmatory License
May 8, 2008
From: THE UNIVERSITY OF ALABAMA AT BIRMINGHAM
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 020916/0574 →
Assignment of Assignor's Interest
Jul 31, 2017
From: MOON, YOUNG-CHOON
To: PTC THERAPEUTICS, INC.
Reel/Frame 043141/0296 →
Assignment of Assignor's Interest
Jul 31, 2017
From: KARP, GARY MITCHELL; HWANG, SEONGWOO; CHEN, GUANGMING; ALMSTEAD, NEIL GREGORY
To: PTC THERAPEUTICS, INC.
Reel/Frame 043141/0219 →
Corrective Assignment to Correct the Inclusion of 6420591,6583309,6503713, 5843995,7029846,7056656, 6468969,6486305,6630294, 6989256,6627398,8247167, 9017935 Previously Recorded on Reel 042418 Frame 0774. Assignor(S) Hereby Confirms the Security Interest.
Aug 24, 2017
From: PTC THERAPEUTICS, INC.
To: MIDCAP FINANCIAL TRUST, AS AGENT
Reel/Frame 043672/0096 →
Release of Security Interest
Jul 14, 2020
From: MIDCAP FINANCIAL TRUST, AS AGENT
To: PTC THERAPEUTICS, INC.
Reel/Frame 053209/0872 →
Security Interest
Oct 28, 2022
From: PTC THERAPEUTICS, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION
Reel/Frame 061803/0878 →
Termination and Release of Patent Security Agreement @ Reel 061803 and Frame 0878
Oct 20, 2023
From: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT
To: PTC THERAPEUTICS, INC.
Reel/Frame 065303/0163 →